New FDA Conflict Of Interest Policy Enacted At MT 100 Committee Meeting
Executive Summary
FDA's new conflict-of-interest disclosure policy for advisory committee members was inaugurated at the Aug. 4 Peripheral & Central Nervous System Drugs Advisory Committee meeting
You may also be interested in...
Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process
FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than an overhaul of its practices
FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members
FDA Advisory Committee Conflict Policy Takes A Toll; Chairs Plan Response
Cardiovascular & Renal Drugs Advisory Committee Chair William Hiatt plans to write an editorial concerning the need for a more transparent conflict of interest policy for panel members